Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review

  title={Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review},
  author={Aisha S. Shariq and Joshua D. Rosenblat and Asem A Alageel and Rodrigo B. Mansur and Carola Rong and Roger Chun-Man Ho and Renee-Marie Ragguett and Zihang Pan and Elisa Brietzke and Roger S. McIntyre},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},

Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review

Orexinergic system is involved in the different psychiatric and neurological disorders; therefore, targeting of this system could be possible novel pathway in the management of these disorders.

Orexin and Psychoneurobiology: A Hidden Treasure

The orexinergic system is involved in different psychiatric and neurological disorders; therefore targeting of this system could be a possible novel pathway in the management of these disorders.

Orexin a levels of adolescents with major depressive disorder

Orexin A levels of the subjects with major depressive disorder are not significantly different from healthy adolescents, and the effect of stress on this relationship would improve the understanding of this issue.

Orexin A in adolescents with anxiety disorders

Orexin-A levels are higher in adolescents with anxiety disorder; however, depressive symptoms should be considered when investigating this relationship.

Antidepressants and Their Impact on Sleep

Preclinical studies have shown potential antidepressant effects of orexin antagonists, which are used to treat insomnia, and low-dose doxepin is the only FDA-approved antidepressant for insomnia.

The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression

Key pathways discussed include neurotransmission, neuroinflammation, clock gene machinery pathways, oxidative stress, role of neurotrophins, stress response pathways, the endocannabinoid and endovanilloid systems, and the endogenous opioid system.

Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder

Switching to suvorexant or eszopiclone was well tolerated and improved the severity of benzodiazepine-unresponsive insomnia in MDD patients.

Interactions between Sleep and Emotions in Humans and Animal Models

It is found that a strong modulatory interaction between sleep processes and emotional states resides on the activity of several key brain structures, such as the amygdala, prefrontal cortex, hippocampus, and brainstem nuclei.



Role of Orexin in the Pathophysiology of Depression: Potential for Pharmacological Intervention

An overview of human and animal research dedicated to the study of the specific involvement of orexins in depression is provided, and a framework in which disturbances of the orexinergic system are regarded as an integral component of the etiology of depression is proposed.

Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.

The synthesis of dual antagonists of orexin receptors are synthesised and these drugs, as opposed to benzodiazepines, do not change the sleep architecture and have limited side-effects.

Neurogenesis-Independent Antidepressant-Like Effects on Behavior and Stress Axis Response of a Dual Orexin Receptor Antagonist in a Rodent Model of Depression

This is the first evidence that pharmacological blockade of the orexinergic system induces a robust antidepressant-like effect and the restoration of stress-related HPA axis defect independently from a neurogenic action.

Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist

Dosed orally Suvorexant significantly and dose-dependently reduced locomotor activity and promoted sleep in rats, dogs, and rhesus monkeys, highlighting a unique opportunity to develop dual orexin antagonists as a novel therapy for insomnia.